Novel therapies in lupus - focus on nephritis.

摘要: Lupus nephritis (LN) is one of the major complications Systemic Erythematosus (SLE) and its treatment remains a challenge. Although classical widely used immunosuppressive agents have accounted for significant improvement in survival decreased progression to end-stage renal failure they lack selectivity underlying immune dysregulation. In addition toxicity related their use relapses after are concern not least because adverse effect on prognosis patients with SLE who kidney involvement. The development more specific pharmacological still research goal. Ideally these should provide better long-term be less toxic. this review we summarise mechanism action results obtained variety drugs that recently been utilized lupus especially those nephritis. We discuss clinical usefulness B- -cell depletion principally anti-CD20 antibodies blockage co-stimulatory pathways (anti-CD40 ligand antibody CTLA4Ig) induction tolerance (LJP 394 peptide vaccination) therapy targeting cytokines (anti-IL10 BLyS blockage) complement system (anti-C5 antibody). Immunoablative doses Cyclophosphamide (CyC) or without Haematopoietic Stem Cell Transplantation (HSCT) possibilities gene also reviewed. intravenous immunoglobulin (IVIg) plasmapheresis discussed treatments practice several years.